Clinical trials: Overweight, Obesity
Obesity, Weight Loss
Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients
The primary objective of this study is to assess, over a period of 12 months, the effect on weight loss and weight maintenance of rimonabant 10 mg in comparison with rimonabant 20 mg in overweight/obese patients after an initial…
- Trial name
- MODERATO (NCT00678483)
- Testing
- rimonabant (SR141716)
- Where
- 5 sites in Croatia, Finland and 3 more
- Volunteers
- 331 people
- Sponsor
- Sanofi
Adverse Drug Event, Side Effects of Drugs
Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure
The aim of this study was to systematically collect data on safety and tolerability of krill powder in humans and simultaneously gain efficacy data by measuring the risk factors for cardiovascular disease.
- Trial name
- NCT03112083
- Testing
- Nutritional counseling A, Nutritional counselling B
- Where
- Finland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Olympic Seafood AS
Weight Loss, Appetite Modulation (Focus of Study)
Safety and Efficacy of IQP-AK-102 in Reducing Appetite
The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several studies demonstrating their efficacy, we are conducting this study to look into the efficacy and safety of this novel combination of…
- Trial name
- NCT02041754
- Testing
- IQP-AK-102
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity, Behavior, Health
Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention
The aim of this study is to compare brain changes in individuals with overweight or obesity enrolled in either the Noom Healthy Weight program or a matched control.
- Conditions
- Obesity, Behavior, Health, Weight Loss
- Trial name
- NCT04522245
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss., Matched Control
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.
- Conditions
- Metabolism and Nutrition Disorder, Obesity, Obstructive Sleep Apnoea
- Trial name
- NCT01557166
- Testing
- liraglutide
- Where
- 42 sites in United States, Canada
- Volunteers
- 359 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide…
- Conditions
- Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD)
- Trial name
- SCORE (NCT06874751)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 45,456 people
- Sponsor
- Novo Nordisk A/S
Bstructive Sleep Apnea (OSA) and Obesity
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity
- Trial name
- NCT06974851
- Testing
- HRS9531
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight and Obesity
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss…
- Trial name
- NCT02041195
- Testing
- Setmelanotide
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week.
- Trial name
- NCT06326060
- Testing
- NNC0519-0130, Tirzepatide
- Where
- 70 sites in United States, Australia and 1 more
- Volunteers
- 354 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity
This study is being done to learn how the study medicine affects the body and how safe it is for people who take it. The researchers will look at a number of health tests, including blood tests such as calcitonin, amylase, and…
- Conditions
- Overweight, Obesity, Healthy
- Trial name
- NCT07400679
- Testing
- PF-08653944
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
NitiNotes' EndoZip System for the Treatment of Obesity
This is first-in-man safety and performance feasibility study, aimed to provide initial clinical assessment of safety and effectiveness of the EndoZip in the treatment of obesity.
- Trial name
- NCT03472196
- Testing
- EndoZip System
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Nitinotes Surgical Ltd.
Metabolism and Nutrition Disorder, Obesity
A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years
This trial is conducted in Europe. The purpose of the trial is to assess safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of liraglutide in obese adolescent subjects aged 12 to 17 years.
- Trial name
- NCT01789086
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Cardiovascular Risk Factor
A Pilot Study to Investigate the Effect of Water-soluble Tomato Extract on TMAO
To determine the effect of 4 weeks daily consumption of Fruitflow on changes in plasma levels of fasting Trimethylamine N-oxide concentrations (TMAO)
- Trial name
- NCT04160481
- Testing
- FruitFlow
- Where
- Ireland
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Healthy Volunteers, Overweight
A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide
The study will look at how two different versions of semaglutide reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different versions.
- Conditions
- Healthy Volunteers, Overweight, Obesity
- Trial name
- NCT04228354
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes
This trial is conducted in Europe. The purpose of the trial is to investigate the effect of insulin detemir on weight change in overweight and obese patients with type 2 diabetes.
- Trial name
- PREDICTIVE™ (NCT00504673)
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- Spain
- Volunteers
- 277 people
- Sponsor
- Novo Nordisk A/S
Hyperlipidemia
Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol
A Multicenter Randomized, Double-Blind, Placebo-Controlled Study to evaluate the efficacy, safety and tolerability of MBX-8025, a novel PPAR-d agonist to treat hyperlipidemia, insulin resistance and obesity in overweight…
- Trial name
- MBX-8025 (NCT00701883)
- Testing
- MBX-8025, Atorvastatin
- Where
- 28 sites in United States
- Volunteers
- 183 people
- Sponsor
- Gilead Sciences
Prader-Willi Syndrome
Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
This Phase 3 study is designed to test the effectiveness of intranasal carbetocin (LV-101) in participants with Prader-Willi syndrome (PWS). Carbetocin is an oxytocin analog (a man-made chemical that is like oxytocin).
- Trial name
- CARE-PWS (NCT03649477)
- Testing
- 3.2 mg intranasal carbetocin, 9.6 mg intranasal carbetocin
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 130 people
- Sponsor
- Levo Therapeutics, Inc.
Overweight, Obesity
A Study Collecting Remote Data in People With an Overweight Condition or Obesity on a Weight Management Program
The purpose of this study is to collect health data related from participants living with an overweight condition in a decentralised clinical study set-up.
- Trial name
- NCT06805539
- Testing
- No treatment given
- Where
- Denmark
- Volunteers
- 146 people
- Sponsor
- Novo Nordisk A/S
Overweight and/or Obesity
STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY
The purpose of the study is to evaluate the effect of formulation on relative bioavailability of PF-06882961.
- Trial name
- NCT04616339
- Testing
- PF-06882961 100 mg
- Where
- Belgium
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- NCT07654361
- Testing
- Aleniglipron
- Where
- 71 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics